These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 19273713)

  • 1. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.
    Terasawa T; Lau J; Bardet S; Couturier O; Hotta T; Hutchings M; Nihashi T; Nagai H
    J Clin Oncol; 2009 Apr; 27(11):1906-14. PubMed ID: 19273713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes.
    Terasawa T; Nagai H
    Leuk Lymphoma; 2009 Nov; 50(11):1750-2. PubMed ID: 19863179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Burggraaff CN; de Jong A; Hoekstra OS; Hoetjes NJ; Nievelstein RAJ; Jansma EP; Heymans MW; de Vet HCW; Zijlstra JM
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):65-79. PubMed ID: 30141066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.
    Terasawa T; Dahabreh IJ; Nihashi T
    Oncologist; 2010; 15(7):750-9. PubMed ID: 20587551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.
    Terasawa T; Nihashi T; Hotta T; Nagai H
    J Nucl Med; 2008 Jan; 49(1):13-21. PubMed ID: 18077527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.
    Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I
    Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
    Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
    Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings.
    Kong Y; Qu L; Li Y; Liu D; Lv X; Han J
    Medicine (Baltimore); 2016 Feb; 95(6):e2808. PubMed ID: 26871850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.
    Adams HJ; Nievelstein RA; Kwee TC
    Br J Haematol; 2015 Aug; 170(3):356-66. PubMed ID: 25868485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different predictive values of interim
    Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
    Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
    Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Moskowitz CH; Zelenetz A; Schoder H
    J Natl Compr Canc Netw; 2010 Mar; 8(3):347-52. PubMed ID: 20202464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.
    Mylam KJ; Nielsen AL; Pedersen LM; Hutchings M
    PET Clin; 2014 Oct; 9(4):443-55, vi. PubMed ID: 26050946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
    Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
    J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.
    Adams HJA; Kwee TC
    Semin Oncol; 2017 Dec; 44(6):404-419. PubMed ID: 29935902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.